Bluebird bio's exit from Europe last year signals rough seas ahead for gene therapy developers, who are trying to gain market access for their products. Evidently, bluebird bio couldn’t strike deals with European payers for its EMA-approved gene therapies, Zynteglo (beti-cel) and Skysona (eli-cel).
Subscribe to:
Post Comments (Atom)
< + > Designing MedTech from the Market Backwards – Life Sciences Today Podcast Episode 64
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. My guest today is Theo Mastrokostop...
No comments:
Post a Comment